

Ifw



Attorney Docket No. VPI/02-137 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/808,678
Confirmation No.: 6199
Filing Date: March 25, 2004
Examiner: Not Yet Assigned
Group art unit: 1632
Applicants: Green et al.
For: COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES

February 9, 2005
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

(a) Pursuant to Rule 56, it is requested that the documents listed on the accompanying 1449 form be considered and made of record in the above-identified patent application. Copy(ies) of references B1-B2, C1-C9 are attached.

(b) ☒ No fee is believed due because:

- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☒ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.


(c) ☐ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

Applicants: Green et al.
Application No.: 10/808,678

- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- ☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,



Michael C. Badia, Reg. No. 51,424
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6467
Fax: (617) 444-6483

Modified Form 1449/PTO

**INFORMATION CLOSURE
STATEMENT BY APPLICANT**

O I P E
FEB 11 2005
PATENT & TRADEMARK OFFICE

Application Number	10/808,678
Filing Date	March 25, 2004
First Named Inventor	Jeremy Green
Group Art Unit	1632
Examiner Name	Not Yet Assigned
Attorney Docket Number	VPI/02-137 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,733,920	Mar. 31, 1998	Mansuri et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	WO	01/53266	Thrombogenix Pty Ltd.	26 July 2001		
	B2	WO	98/17662	Novartis Ag	30 April 1998		

OTHER NON-PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1	Edwards et al., "Antineoplastic Activity and Cytotoxicity of Flavones, Isoflavones, and Flavanones", Abstract XP-009035912, J. of Natural Products, Pages 85-91, 1979.					
	C2	Database Chemabs, "Amino Acid Derivatives and Oximes of Flavones" Abstract XP-002295239, Chem. Of Heterocyclic Compounds, 2002.					
	C3	Database Chemabs, "Benzo-gamma-pyrones. Part XIV. Reaction of C-substituted 2-phenyl-4H-1-benzopyran-4-ones with hydroxylamine", Abstract XP-002295240, Polish J. of Chem., 1991.					
	C4	Sen et al., "Search for New Antimalarials. Part V. Synthesis of Some 8-aminoalkylamino- and 8-dialkylaminoalkylamino-chromones", Abstract XP-009035940, J. of the Indian Chem. Soc., Calcutta, Pages 217-222, 1960.					
	C5	Weng, Lingling, et al., Database Chemabs, "Preparation of Isoflavone Alicyclic Ethers and Oxime Derivatives", Abstract XP-002295241, Materia Medica Inst., Huaxi Med. College, Peop. Rep. China, 1993.					
	C6	Beugelmans et al., "Action of Hydroxylamine on Chromone and Khellin. Oxime vs. Isoxazoles Structures", XP-002295236, J. of Organic Chem., Vol. 42, No. 8, Pages 1356-1360, 1977.					
	C7	Database Chemab, "Thiazole Analogs of Isoflavones", Abstract XP-002295242, Khimichni ta Biologichni Nauki, 1980.					
	C8	Spatz et al., "7,2',4'-Trimethoxyflavone", J. of Organic Chem., Abstract XP-002295237, Vol. 24, No. 9, Pages 1381-1382, 1959.					
	C9	Eiden et al., "Über die Reaktion Von Hydroxylamin Mit 2,6-Dimethyl-3-Acetylchromon", Tetrahedron Letters, Abstract XP-002295238, Vol. 17, Pages 1439-1442, 1970.					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



Our Docket No.: VPI/02-137 US

Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On February 9, 2005
Date

1. Information Disclosure Statement (3 pages, in duplicate);
2. PTO-1449 Form (1 page, in duplicate);
3. Cited References (A1; B1-B2; C1-9); and
4. This Return Postcard Receipt.

Signature

Karen DiRocco

Typed or printed name of person signing Certificate